Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model

Sung Yi Hong, Myun Hee Lee, Kyung Sup Kim, Hyun Cheol Jung, Jae Kyung Roh, Woo Jin Hyung, Sung Hoon Noh, Seung Ho Choi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Aim: rAAV mediated endostatin gene therapy has been examined as a new method for treating cancer. However, a sustained and high protein delivery is required to achieve the desired therapeutic effects. We evaluated the impact of topoisomerase inhibitors in rAAV delivered endostatin gene therapy in a liver tumor model. Methods: rAAV containing endostatin expression cassettes were transduced into hepatoma cell lines. To test whether the topoisomerase inhibitor pretreatment increased the expression of endostatin, Western blotting and ELISA were performed. The biologic activity of endostatin was confirmed by endothelial cell proliferation and tube formation assays. The anti-tumor effects of the rAAV-endostatin vector combined with a topoisomerase inhibitor, etoposide, were evaluated in a mouse liver tumor model. Results: Topoisomerase inhibitors, including camptothecin and etoposide, were found to increase the endostatin expression level in vitro. The over-expressed endostatin, as a result of pretreatment with a topoisomerase inhibitor, was also biologically active. In animal experiments, the combined therapy of topoisomerase inhibitor, etoposide with the rAAV-endostatin vector had the best tumor-suppressive effect and tumor foci were barely observed in livers of the treated mice. Pretreatment with an etoposide increased the level of endostatin in the liver and serum of rAAV-endostatin treated mice. Finally, the mice treated with rAAV-endostatin in combination with etoposide showed the longest survival among the experimental models. Conclusion: rAAV delivered endostatin gene therapy in combination with a topoisomerase inhibitor pretreatment is an effective modality for anticancer gene therapy.

Original languageEnglish
Pages (from-to)1191-1197
Number of pages7
JournalWorld Journal of Gastroenterology
Volume10
Issue number8
DOIs
Publication statusPublished - 2004 Apr 15

Fingerprint

Topoisomerase Inhibitors
Endostatins
Dependovirus
Genetic Therapy
Liver
Neoplasms
Etoposide
Camptothecin
Therapeutic Uses

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Hong, Sung Yi ; Lee, Myun Hee ; Kim, Kyung Sup ; Jung, Hyun Cheol ; Roh, Jae Kyung ; Hyung, Woo Jin ; Noh, Sung Hoon ; Choi, Seung Ho. / Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model. In: World Journal of Gastroenterology. 2004 ; Vol. 10, No. 8. pp. 1191-1197.
@article{16a69eb217dc4ae1938b5138a6215a37,
title = "Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model",
abstract = "Aim: rAAV mediated endostatin gene therapy has been examined as a new method for treating cancer. However, a sustained and high protein delivery is required to achieve the desired therapeutic effects. We evaluated the impact of topoisomerase inhibitors in rAAV delivered endostatin gene therapy in a liver tumor model. Methods: rAAV containing endostatin expression cassettes were transduced into hepatoma cell lines. To test whether the topoisomerase inhibitor pretreatment increased the expression of endostatin, Western blotting and ELISA were performed. The biologic activity of endostatin was confirmed by endothelial cell proliferation and tube formation assays. The anti-tumor effects of the rAAV-endostatin vector combined with a topoisomerase inhibitor, etoposide, were evaluated in a mouse liver tumor model. Results: Topoisomerase inhibitors, including camptothecin and etoposide, were found to increase the endostatin expression level in vitro. The over-expressed endostatin, as a result of pretreatment with a topoisomerase inhibitor, was also biologically active. In animal experiments, the combined therapy of topoisomerase inhibitor, etoposide with the rAAV-endostatin vector had the best tumor-suppressive effect and tumor foci were barely observed in livers of the treated mice. Pretreatment with an etoposide increased the level of endostatin in the liver and serum of rAAV-endostatin treated mice. Finally, the mice treated with rAAV-endostatin in combination with etoposide showed the longest survival among the experimental models. Conclusion: rAAV delivered endostatin gene therapy in combination with a topoisomerase inhibitor pretreatment is an effective modality for anticancer gene therapy.",
author = "Hong, {Sung Yi} and Lee, {Myun Hee} and Kim, {Kyung Sup} and Jung, {Hyun Cheol} and Roh, {Jae Kyung} and Hyung, {Woo Jin} and Noh, {Sung Hoon} and Choi, {Seung Ho}",
year = "2004",
month = "4",
day = "15",
doi = "10.3748/wjg.v10.i8.1191",
language = "English",
volume = "10",
pages = "1191--1197",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "8",

}

Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model. / Hong, Sung Yi; Lee, Myun Hee; Kim, Kyung Sup; Jung, Hyun Cheol; Roh, Jae Kyung; Hyung, Woo Jin; Noh, Sung Hoon; Choi, Seung Ho.

In: World Journal of Gastroenterology, Vol. 10, No. 8, 15.04.2004, p. 1191-1197.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model

AU - Hong, Sung Yi

AU - Lee, Myun Hee

AU - Kim, Kyung Sup

AU - Jung, Hyun Cheol

AU - Roh, Jae Kyung

AU - Hyung, Woo Jin

AU - Noh, Sung Hoon

AU - Choi, Seung Ho

PY - 2004/4/15

Y1 - 2004/4/15

N2 - Aim: rAAV mediated endostatin gene therapy has been examined as a new method for treating cancer. However, a sustained and high protein delivery is required to achieve the desired therapeutic effects. We evaluated the impact of topoisomerase inhibitors in rAAV delivered endostatin gene therapy in a liver tumor model. Methods: rAAV containing endostatin expression cassettes were transduced into hepatoma cell lines. To test whether the topoisomerase inhibitor pretreatment increased the expression of endostatin, Western blotting and ELISA were performed. The biologic activity of endostatin was confirmed by endothelial cell proliferation and tube formation assays. The anti-tumor effects of the rAAV-endostatin vector combined with a topoisomerase inhibitor, etoposide, were evaluated in a mouse liver tumor model. Results: Topoisomerase inhibitors, including camptothecin and etoposide, were found to increase the endostatin expression level in vitro. The over-expressed endostatin, as a result of pretreatment with a topoisomerase inhibitor, was also biologically active. In animal experiments, the combined therapy of topoisomerase inhibitor, etoposide with the rAAV-endostatin vector had the best tumor-suppressive effect and tumor foci were barely observed in livers of the treated mice. Pretreatment with an etoposide increased the level of endostatin in the liver and serum of rAAV-endostatin treated mice. Finally, the mice treated with rAAV-endostatin in combination with etoposide showed the longest survival among the experimental models. Conclusion: rAAV delivered endostatin gene therapy in combination with a topoisomerase inhibitor pretreatment is an effective modality for anticancer gene therapy.

AB - Aim: rAAV mediated endostatin gene therapy has been examined as a new method for treating cancer. However, a sustained and high protein delivery is required to achieve the desired therapeutic effects. We evaluated the impact of topoisomerase inhibitors in rAAV delivered endostatin gene therapy in a liver tumor model. Methods: rAAV containing endostatin expression cassettes were transduced into hepatoma cell lines. To test whether the topoisomerase inhibitor pretreatment increased the expression of endostatin, Western blotting and ELISA were performed. The biologic activity of endostatin was confirmed by endothelial cell proliferation and tube formation assays. The anti-tumor effects of the rAAV-endostatin vector combined with a topoisomerase inhibitor, etoposide, were evaluated in a mouse liver tumor model. Results: Topoisomerase inhibitors, including camptothecin and etoposide, were found to increase the endostatin expression level in vitro. The over-expressed endostatin, as a result of pretreatment with a topoisomerase inhibitor, was also biologically active. In animal experiments, the combined therapy of topoisomerase inhibitor, etoposide with the rAAV-endostatin vector had the best tumor-suppressive effect and tumor foci were barely observed in livers of the treated mice. Pretreatment with an etoposide increased the level of endostatin in the liver and serum of rAAV-endostatin treated mice. Finally, the mice treated with rAAV-endostatin in combination with etoposide showed the longest survival among the experimental models. Conclusion: rAAV delivered endostatin gene therapy in combination with a topoisomerase inhibitor pretreatment is an effective modality for anticancer gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=2342426204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342426204&partnerID=8YFLogxK

U2 - 10.3748/wjg.v10.i8.1191

DO - 10.3748/wjg.v10.i8.1191

M3 - Article

C2 - 15069724

AN - SCOPUS:2342426204

VL - 10

SP - 1191

EP - 1197

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 8

ER -